INTRODUCTION
Klebsiella pneumoniae is the fourth most common cause of bacteraemia in Western Australia (Inglis et al., 2008) . It is associated with more severe disease and greater patient mortality than other Gram-negative bacteria (Ko et al., 2002; Yu et al., 2007) . K. pneumoniae isolates are able to evade host immune defences, increasing their invasiveness and ability to cause disease (Chung et al., 2008) . The genotypic diversity amongst invasive isolates varies by region, often with one genotype involved in a disproportionate number of infections (Bochud et al., 2004; Decré et al., 2011) .
The successful management of invasive K. pneumoniae infections requires prompt administration of an effective antimicrobial agent (Paterson et al., 2004) . Viable therapeutic options have been diminished by the emergence of resistance in K. pneumoniae (Queenan & Bush, 2007) . In the 1980s, Ambler class A and C b-lactamases capable of hydrolysing ceftriaxone and ceftazidime were acquired [extended-spectrum b-lactamases (ESBLs) and plasmidmediated AmpCs, respectively] (Livermore et al., 2007) . Meropenem use increased as a result of ceftriaxone resistance, which in turn promoted the emergence of carbapenem-resistant K. pneumoniae isolates (Rhomberg & Jones, 2009 ). This phenomenon was observed in New York City hospitals where continued meropenem use contributed to K. pneumoniae carbapenemase (KPC)-3-producing ST258 (first detected in 2004) becoming the predominant genotype (Gomez-Simmonds et al., 2015; Rhomberg & Jones, 2009; Woodford et al., 2004) .
Western Australia was the first Australian state to report SHV ESBLs in 1985 after their importation by returning international travellers (Mulgrave & Attwood, 1993) . Today, the CTX-M-15 ESBL is established in the invasive K. pneumoniae population in Western Australia (Turnidge et al., 2014b) and its neighbouring regions (Cantó n et al., 2012) . Approximately 60% of the K. pneumoniae isolates in the Southeast Asian and Indian subcontinent regions are ceftazidime-resistant, and set the scene for increased carbapenem resistance (Castanheira et al., 2011) . We examined locally obtained invasive and multiresistant isolates for newly introduced b-lactamases (Peirano et al., 2011) , and compared them with historical isolates. We aimed to investigate long-term trends in b-lactam resistance in Western Australia and their association with the appearance of the more successful K. pneumoniae resistant genotypes.
METHODS
Bacterial strains. We obtained K. pneumoniae isolates from 23 hospitals across Western Australia (12 regional, 11 Perth Metropolitan) for a series of cross-sectional snapshot investigations. Our collection comprised isolates stored in the historical archive (freeze-dried) and the sterile-site collection (280 uC, glycerol brain heart infusion) of the Western Australian Culture Collection, which were reconstituted by suspension in tryptone soya broth, plated onto blood agar, incubated at 37 uC for 48 h and confirmed as K. pneumoniae by matrix-assisted laser desorption ionization time-of-flight MS analysis (MALDI Biotyper; Bruker-Daltonics). This K. pneumoniae isolate collection comprised: (i) multiresistant isolates (n521) from January 2011 to February 2015 resistant to at least three antibiotic classes including an extended-spectrum cephalosporin (ceftazidime or ceftriaxone); (ii) from March 2010 to March 2011, invasive isolates (n598) from consecutive blood cultures and other sterile sites; and (iii) from 1977 to 2008, stored historical isolates (n550) from sterile-site specimens. We obtained clinical and infection control data where available for each isolate. The patients with isolates in the multiresistant collection had a median age of 58 years (range 13-94 years). Patients had K. pneumoniae isolated from their urine in 11 of 21 cases. The remainder had K. pneumoniae isolated from: sputum (n52), wound swabs (n52), rectal swabs (n52), blood cultures (n52), pleural fluid (n51) and peritoneal aspirate (n52). Two patients had received renal transplants, three patients suffered neurological disorders (cranial trauma, Guillian-Barré and hypoxic brain injury) requiring intensive care in a high-risk country prior to an international inter-hospital transfer to Western Australia and one patient had an infected diabetic leg ulcer. The patients with isolates in the sterile-site invasive isolate collection had a median age of 67.5 years (range 32-100 years) and half had K. pneumoniae isolated from blood cultures taken at one of 10 local emergency departments. Six patients had malignancies (including leukaemia, bowel, bladder, prostate and pancreatic cancer), 10 had hepatobiliary or pancreatic diseases, six had intestinal disease (predominantly bowel obstructions), four had diabetes with hyperglycaemia or ketosis and three had neutropenia of undetermined aetiology.
String test for hyper-viscosity. Cultures were grown overnight at 37 uC on blood agar. A bacteriological loop was used to test colonies for the formation of 'strings' of viscous extracapsular polysaccharide. A string length w5 mm was considered to indicate hyper-viscosity (Fang et al., 2004) .
Antimicrobial susceptibility tests. Antimicrobial susceptibility testing was performed against the locally used range of antibiotics, i.e. amoxicillin with and without clavulanate, norfloxacin, ciprofloxacin, nitrofurantoin, trimethoprim with and without sulfamethoxazole, cephalothin, cefazolin, meropenem, gentamicin, tobramycin, amikacin, ceftriaxone with and without clavulanate, aztreonam, ticarcillin clavulanate, colistin, ceftazidime, cefepime, cefoxitin and piperacillin/ tazobactam, using agar dilution (Wiegand et al., 2008) and interpreted using Clinical and Laboratory Standards Institute breakpoints (CLSI, 2011) . The definitive meropenem MICs for isolates growing above a 0.25 mg l 21 screening threshold were determined using Etests (bioMérieux) or by microbroth dilution when MICs were above the upper limit of the Etest strip (32 mg l 21 ).
Molecular detection of resistance mechanisms. b-Lactamase and carbapenemase genes were detected by PCR assay. Briefly, K. pneumoniae template DNA was prepared from three colonies of each isolate suspended in 1 ml ultrapure PCR-grade water. Suspensions were heated to 95 uC for 5 min and centrifuged at 14 000 g. PCR assays were performed on extracts from all isolates to detect b-lactamase genes from the AmpC (bla ACC , bla CIT , bla DHA , bla EBC , bla FOX and bla MOX ) and ESBL families (bla CTX-M , bla SHV and bla TEM ) (Dallenne et al., 2010; Fang et al., 2008; Pérez-Pérez & Hanson, 2002) .
Isolates with a meropenem MIC i0.25 mg l 21 were examined for the presence of carbapenemases using in-house PCR assays that targeted sequences within bla IMP , bla VIM , bla NDM , bla KPC , bla VIM , bla IMP and bla OXA-48-like .
Porin mutations contributing to carbapenem resistance, including premature stop codons, deletions inducing frameshift and third eyelet insertions, were sought by amplifying and sequencing the K. pneumoniae ompK35 and ompK36 loci of all multiresistant isolates in the collection (Landman et al., 2009) . All PCR amplicons were sequenced (3130xl; Applied Biosystems), and chromatograms were edited and assembled using Main Workbench 7.5.1 (CLC) and identified by BLAST.
Molecular typing. Three genotyping methods were used to investigate the genotypic diversity of Western Australian K. pneumoniae isolates: (i) DNA macro-restriction analysis by PFGE to find closely related isolates, (ii) variable number tandem repeat (VNTR) assay to provide enhanced genotype resolution (Maslow et al., 1993; Turton et al., 2010) and (iii) multilocus sequence typing (MLST) on all multiresistant, historical or invasive isolates from PFGE groups with i60% similarity (Diancourt et al., 2005) . Novel allelic combinations were submitted for sequence type assignment to the K. pneumoniae database curated by the Institut Pasteur. A minimum spanning tree was generated from MLST allelic profiles using the goeBURST algorithm in PHYLOViZ 1.1 (Francisco et al., 2009 ).
Sequences were edited, alignments created and neighbour-joining trees constructed with MainWorkbench 7.5.1 (CLC). Neighbourjoining trees were constructed from in silico translated sequence data using the Kimura Protein algorithm (100 bootstraps). Maximumlikelihood phylogenetic trees were reconstructed from concatenated MLST sequences using the General Time Reversible and WAG models (500 bootstraps). Two epidemiological outliers were included in the MLST analyses by sequencing a historical K. pneumoniae reference strain ATCC 13883 and concatenating the homologous sequences from the published Klebsiella oxytoca KCTC 1686 genome (Shin et al., 2012) .
Statistical and bioinformatics methods. Descriptive statistics and the Mann-Whitney U-test were performed with biostatistics software (Prism 5.0d; GraphPad), using a significance threshold of Pj0.05. We analysed PFGE results with BioNumerics 6.5 (Applied Maths) (Maslow et al., 1993) .
RESULTS
Only narrow-spectrum Ambler class A b-lactamases were detected in Western Australian historical K. pneumoniae isolates from 1977 until 1988. These were chromosomal bla SHV-1/SHV-11/LEN and plasmid-borne bla TEM-1 enzymes (Fig. 1) . Prior to 1989, antimicrobial resistance in K. pneumoniae was limited to amoxicillin/clavulanate, cephalothin, cefazolin, co-trimoxazole and aminoglycosides. Ceftriaxone resistance was first observed in an ST2002 bla SHV-2a -positive isolate from 1989 and then detected in isolates from subsequent decades (Tables 1 and 2 Table 3 ). During this period we also encountered three non-invasive, non-carbapenemaseproducing, bla CTX-M-15 -positive isolates in the multiresistant population. Only one of these patients had a travel history consistent with overseas acquisition. All other ESBL and AmpC b-lactamases observed (bla CTX-M-14 , bla CTX-M-9 , bla CMY-4 and bla DHA-1 ) were from the multiresistant isolate collection. The only isolate recovered from a blood culture specimen was an ST37 bla CTX-M-14 K. pneumoniae (Table 3 ). The appearance of SHV ESBLs corresponded with the first detection of ceftriaxone-resistant K. pneumoniae isolates in Western Australia. Ceftazidime resistance was first detected soon after in 1993 and continues to be detected in invasive isolates. From 2011 onwards, ceftriaxone and ceftazidime resistance was conferred by CTX-M-14 and CTX-M-15 b-lactamases, whilst SHV ESBL enzymes were notably absent. Meropenem resistance in K. pneumoniae appeared after ceftazidime resistance. We encountered meropenem-resistant K. pneumoniae isolates from 2011 onwards, all of which were from the multiresistant isolate collection (nine of 21 isolates). Carbapenemase-producing isolates were from the multiresistant isolate collection in which we detected the IMP-4 (n56), NDM-1 (n54), OXA-181 (n52), KPC-3 (n51) and VIM-4 (n51) carbapenemase and ompK36 (n56) mutations. Only one meropenem-resistant bla VIM-4 -positive K. pneumoniae was isolated from a blood culture, whilst the remainder were from urine cultures, rectal swabs, wound swabs or pleural fluids. There was no history of recent overseas travel or room-sharing from any patient with bla IMP-4 (Table 3) . Porin mutations were present only in carbapenemase-positive isolates from patients with links to other regions. Isolates with porin mutations had a significantly higher meropenem MIC (median + SD: 160 + 111.6 mg l
21
) than those without (1 + 0.68 mg l 21 ; P50.003).
We found a large amount of genotypic diversity amongst Western Australian K. pneumoniae sequence types and pulsotypes. We encountered 50 isolates grouped as 21 pulsotype clusters which in one instance did not correspond with MLST clustering (18 sets of two pulsotypes, one set of three pulsotypes, one set of four pulsotypes, three isolates acquired from the same patient, and one set of nine pulsotypes, 119/169, 70.4% singletons). In 14 instances PFGE-grouped isolates had dissimilar VNTR profiles and all groups lacked tempero-spatial clustering. We observed 77 distinct sequence types amongst the 96 isolates genotyped by MLST. Of these sequence types, 28 (ST1965-ST1990, ST1992 and ST2002) were previously unidentified (Figs 2 and 3) . Singletons accounted for 84.42% of all sequence types and nine of the 12 recurring sequence types were obtained either from the same patient in concurrent specimens from different infection sites or from specimens taken several months apart. Another three recurring sequence types (ST23, ST86 and a previously unidentified ST1980) were isolated from multiple patients. The two ST1980 isolates found in this study were collected 32 years apart (1980 and 2012) . The more recent isolate of these had acquired bla CTX-M-15 and bla IMP-4 b-lactamases. ST86 isolates formed Western Australia's commonest recurrent invasive pulsotype (nine of 148, 6.1% of isolates). By PFGE, ST86 isolate PFGE profiles from 1977 to 2011 clustered at the 90% similarity level. The historical ST86 isolate D2863 differed from its closest contemporary by one repeat at LocN1; other historical isolate VNTR profiles differed from contemporary ST86 isolates by three loci (contemporary isolates had lost loci E, H and I). ST86 K. pneumoniae infections were community-acquired and geographically unconnected. We detected a new recurring (100) 21 (100) (100) 
DISCUSSION
Between January 1985 and June 1991, Western Australia was the first Australian state to encounter ESBLs in K. pneumoniae (Mulgrave & Attwood, 1993) . Those ESBLs were from the bla SHV family, and were present in our collection of isolates between 1989 and 2001. CTX-M enzymes appear to have replaced SHV ESBLs from the local K. pneumoniae population (Song et al., 2009) . It is possible that returning international travellers imported these b-lactamases into Western Australia, similar to European observations (Livermore et al., 2007; Peirano et al., 2011; Rogers et al., 2012) . Both CTX-M-14 and CTX-M-15 are present in Southeast Asia and the Indian subcontinent, both common destinations for Western Australian travellers. We also found a long-term trend in the expansion of b-lactam resistance, in line with what was observed in 2004 North American K. pneumoniae isolates (Rhomberg & Jones, 2009) .
A single-centre study conducted in New York City found hospital-acquired, KPC-producing ST258 to be the predominant K. pneumoniae genotype isolated from bloodstream infections (Gomez-Simmonds et al., 2015) . The overall genotypic diversity at the MLST level of New York City K. pneumoniae was high, and there was little overlap between antibiotic-susceptible, ESBL-producing and carbapenem-resistant genotypes. However, the genotypic diversity within these MLST groups was not determined. Carbapenemases encountered in New York City isolates belonged to the endemic KPC family (KPC-2 and KPC-3).
No non-endemic enzymes (VIM, IMP, OXA-48-like, b-Lactam resistance trends in K. pneumoniae NDM) were encountered. The majority of the New York City ST258 infections were acquired following admission to an intensive care unit. In contrast, Western Australian ST86 isolates were detected in blood cultures obtained from patients with community-acquired infections at local emergency departments from septic, febrile and hyperglycaemic patients. In our study of isolates from multiple centres in Western Australia we found a similar degree of genotypic diversity amongst the K. pneumoniae isolates. Genotypic diversity within Western Australia's ST86 lineage was low irrespective of whether the isolate was ceftazidime-susceptible or ceftazidime-resistant. Our study indicates that the IMP-4 carbapenemase remains endemic in Western Australia since a previous report (Turnidge et al., 2014b (Rhomberg & Jones, 2009) . Prospective collaborative studies are required to accurately document the epidemiology of carbapenem resistance at regional and international levels.
Western Australian K. pneumoniae were marginally less diverse than the previous Australian estimate (84.42 and 95% distinct, respectively) (Holt et al., 2015) . However, the previous estimate was generated using a small sample size (n540) which may have overestimated diversity, whereas this study allowed for the inclusion of duplicate Fig. 2 . goeBURST minimum spanning tree of Western Australian K. pneumoniae sequence types, represented by numbered boxes. Numbers above branches represent the locus difference between connected genotypes and coloured boxes represent isolate collections: invasive collection (red), multiresistant organism collection (blue) and historical collection (yellow). A mix of two primary colours was used to indicate sequence types encountered in two collections: invasive and multiresistant organism collections (purple), invasive and historical collections (orange), and historical and multiresistant organism collections (green). The unboxed ST3 isolate represents the ATCC 13883 reference strain.
MRO isolates, potentially underestimating diversity. ESBLs encountered in Western Australian K. pneumoniae predominantly belonged to the CTX-M-1 group and to a lesser extent the CTX-M-9 group, which is consistent with national surveillance findings (Turnidge & Bell, 2014a) . Western Australian IMP-4-producing sequence types were different from those encountered in Queensland, and also unlike Queensland, repeat non-epidemiologically linked sequence types were detected in Western Australia (Sidjabat et al., 2015) . Despite detecting non-endemic carbapenemases in Western Australia, there was only one documented case of patient-to-patient transfer. Unlike the Eastern states, no case clusters of non-endemic carbapenemase-producing K. pneumoniae have occurred in Western Australia to date (Chang et al., 2015; Espedido et al., 2013; Tai et al., 2015) .
We found that a hyper-viscous ST86 genotype has been present in Western Australia since 1977. This was the dominant invasive sequence type between 1977 and 2011, and appears to be community-acquired (Bochud et al., 2004) . In the 2010s, a second invasive sequence type ST23 appeared in Western Australia, causing liver abscesses and metastatic disease in local patients. Isolates belonging to ST23 are the dominant cause of liver abscess in neighbouring regions (Siu et al., 2011) . Further investigations are required to determine the prevalence of ST23 and ST86 in Western Australia (Dulku & Tibballs, 2014) , and to monitor these sequence types for acquired b-lactam resistance.
Antimicrobial resistance gains are thought to be at the expense of virulence in a process of reductive evolution (Tsai et al., 2011) . However, ESBL-resistant K. pneumoniae continued to be isolated from clinical specimens during a period of 12 years. Other studies indicate that acquisition of ESBLs by invasive genotypes is not necessarily associated with attenuated virulence (Bialek-Davenet et al., 2014).
We used a cross-sectional study design for this investigation of Western Australian K. pneumoniae that limited the scope for comparing separate collections. Due to low rates of ESBL and carbapenem-resistant Enterobacteriaceae isolates, the multiresistant isolate collection selection criteria favoured resistant isolates and therefore could not be used to calculate resistance rates or the prevalence of specific molecular mechanisms. We used assays targeting existing resistance mechanisms and we were therefore unable to determine if non-target b-lactam resistance mechanisms emerged in Western Australia. However, our investigation provides a series of molecular epidemiological snapshots of resistance mechanisms in Western Australian K. pneumoniae.
In summary, we have observed the consecutive appearance of ceftriaxone, ceftazidime, aztreonam and meropenem resistance in Western Australia over a 21-year period. Ceftazidime resistance first appeared in 1993 and CTX-M b-lactamases have replaced SHV ESBLs in Western Australian invasive K. pneumoniae isolates. ESBL-positive isolates continue to cause invasive disease in Western Australia and appear to persist without loss of virulence.
